1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Takeda And Shire - One Japan CEO's Take

 
• By Ian Haydock

The planned combination of Takeda and Shire has dominated headlines in recent weeks, but how is it viewed within the industry in Japan? One CEO shares his thoughts.

Puzzle
TAKEDA AND SHIRE HEAD FOR INTEGRATION • Source: Shutterstock

The planned $64bn effective merger between Takeda Pharmaceutical Co. Ltd. and its larger acquisition target Shire PLC has dominated the pharma industry headlines and commentary over the past few weeks, but has received a mixed reception from analysts and commentators, and from some Takeda investors worried over the financing of the deal, its impact on future share performance, and whether the two large companies can be fully integrated successfully.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m

 
• By Ian Haydock

The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By Lisa Takagi

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

Eisai Expands Dementia Ecosystem Via EcoNaviSta Acquisition

 
• By Lisa Takagi

Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.

Multiple Factors Behind Accelerating Private Equity Plays In Japan, APAC

 
• By Ian Haydock and Lisa Takagi

With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.

More from Focus On Asia